Concepedia

Giridhar Tirucherai

GT

Statistics

Publications

26

Citations

1.8K

H-Index

20

Active since

1999

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Sweden)

University of Missouri–Kansas City

University of California San Diego

Texas Liver Institute

Giridhar Tirucherai is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, pharmacy, and pharmacotherapy.

Publications per year

1999–2025

26

Publications

26

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis

Xiaoli Wang, Giridhar Tirucherai, Thomas Marbury et al. · The Journal of Clinical Pharmacology · 2015 · 284 citations · Full text

, , +17

Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

Edgar D. Charles, Brent A. Neuschwander‐Tetri, Juan P. Frías et al. · Obesity · 2018 · 248 citations · Full text

, , +17

Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects

Xiaoli Wang, Sabiha Mondal, Jessie Wang et al. · American Journal of Cardiovascular Drugs · 2013 · 154 citations · Full text

, , +17

Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial

Adam L. Boxer, Irfan Qureshi, Michael K. Ahlijanian et al. · The Lancet Neurology · 2019 · 141 citations

, , +10

BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial

Eric Lawitz, Diane E. Shevell, Giridhar Tirucherai et al. · Hepatology · 2021 · 100 citations · Full text

, , +17

1–5 of 26